Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

Use of Continuous Circadian Intracerebroventricular Administration of Anaerobic-Dopamine Reduces Levodopa-Related Complications

Media Contact: Shea Higgins +1 304-633-3396, 

MILWAUKEE, WI, USA – Use of continuous intracerebroventricular (i.c.v.) administration of anaerobic dopamine (A-dopamine) showed a significant reduction in dyskinesias in a study released today at International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain. 

Long-term use of levodopa/carbidopa often leads to development of unwanted motor symptoms in patients with Parkinson’s disease. These unwanted motor symptoms are termed levodopa-induced dyskinesias. Many alternate therapy options have been investigated as ways to stave off dyskinesia. 

Moreau et al. and colleagues developed early clinical trials to assess the practicality of using i.c.v administration of dopamine. These early investigations failed due to the accelerated dopamine oxidation and tachyphylacxia. Their most recent investigation sought to investigate the safety and efficacy of i.c.v. of A-dopamine treatment versus the standard oral treatment in treating levodopa-related complications (LDRC). A total of four patients were assessed over two 1-month periods in an open-label randomized trial. Use of i.c.v. A-dopamine showed a greater reduction in dyskinesias compared to the standard oral treatment.  

Stella Papa, Professor in the Department of Neurology at the Emory School of Medicine, responded to this study, “It is a significant result in four patients, which deserves attention. An alternative to oral treatment that reduces dyskinesias and ‘off’ periods between 80% to almost disappearance has a large effect. Results also show dose-dependent effect size, adding support to the data.” 

Full abstract text: Reference #: 1030

# # # 

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:
The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options. 

About the International Parkinson and Movement Disorder Society: 
The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice